FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

叶黄素 医学 吉西他滨 福尔菲里 伊立替康 肿瘤科 内科学 胰腺癌 随机对照试验 无进展生存期 化疗 总体生存率 癌症 结直肠癌
作者
Laétitia Dahan,Jean Marc Phelip,Karine Le Malicot,Nicolas Williet,Jérôme Desrame,Julien Volet,C. Pétorin,David Malka,Christine Rebischung,Thomas Aparicio,Cédric Lecaille,Yves Rinaldi,Anthony Turpin,Anne Bignon,Jean‐Baptiste Bachet,Jean François Seitz,Côme Lepage,Ετιεννε François
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): 4000-4000 被引量:40
标识
DOI:10.1200/jco.2018.36.15_suppl.4000
摘要

4000 Background: Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis (5-year overall survival [OS] <5%). Our previous trial (PRODIGE4-ACCORD11) has demonstrated the superiority of 6-month [m] chemotherapy with FOLFIRINOX over gemcitabine in terms of progression-free survival [PFS] (6.4 vs. 3.3 m; HR: 0.47; 95%CI: 0.37-0.59; p<0.001) and OS (11.1 vs. 6.8 m; HR: 0.57; 95%CI: 0.45-0.73; p<0.001), at the expense of higher toxicity, notably cumulative, often limiting, peripheral neuropathy with oxaliplatin. In this randomized Phase II trial, we aimed to assess an oxaliplatin ‘stop-and-go’ strategy and an alternative sequential strategy in mPC. Methods: Patients (pts) were randomized to receive either 6m FOLFIRINOX (arm A), 4m FOLFIRINOX followed by LV5FU2 maintenance treatment for controlled pts, and treatment reintroduction at disease progression (arm B), or a sequential treatment alternating gemcitabine and FOLFIRI.3 every 2m (arm C). The primary endpoint was to evaluate the 6m-PFS rate (H0: 30%, H1: 45%, Fleming design) in order to select the best therapeutic strategy for a future Phase III clinical trial. Results: Between Jan 2015 and Nov 2016, 273 pts (mean age: 63 years; range: 40-76) were enrolled (A: 91; B: 92; C: 90). The median durations of treatment were 5.1, 6.2, and 4.4 m in A, B, and C respectively. Grade 3/4 neurotoxicity occurred in 10% of pts in arm A and 19% of pts in arm B. Median ratio of oxaliplatin was 83% in A and 92% in B. 6m-PFS rates were 47% in A, 44% in B, and 34% in C. 4m objective response rates were 35% in A, 41% in B, and 17% in C. Median PFS was respectively 6.3, 5.7 and 4.5 m in A, B and C. Median OS was 10.1 in A, 11.2 in B and 7.3 m in C. The median duration of first maintenance therapy in B was 3.3 m (range: 0.03-22.6). Conclusions: Maintenance with LV5FU2 appears to be feasible and effective in patients with mPC controlled after 4m of induction chemotherapy with FOLFIRINOX. Severe neurotoxicity rate was higher in the maintenance therapy arm, likely because of higher cumulative oxaliplatin dose.1Conroy NEJM 2011. Clinical trial information: NCT02352337.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
33发布了新的文献求助10
刚刚
1秒前
1秒前
彭于晏应助阿白采纳,获得10
2秒前
2秒前
优美鱼发布了新的文献求助10
2秒前
人参完成签到,获得积分10
3秒前
3秒前
从容的雨灵完成签到,获得积分10
3秒前
留胡子的立辉完成签到,获得积分10
4秒前
wzx完成签到,获得积分10
5秒前
起风了发布了新的文献求助10
5秒前
LZM完成签到,获得积分10
6秒前
6秒前
赘婿应助xwz采纳,获得10
6秒前
6秒前
人参发布了新的文献求助10
6秒前
7秒前
8秒前
123完成签到 ,获得积分10
9秒前
sure发布了新的文献求助10
10秒前
10秒前
11秒前
11秒前
wzx发布了新的文献求助10
12秒前
和谐的小懒猪完成签到 ,获得积分10
12秒前
13秒前
老实莫言发布了新的文献求助30
14秒前
研友_VZG7GZ应助秀丽笑容采纳,获得10
14秒前
15秒前
wendinfgmei发布了新的文献求助10
16秒前
16秒前
香蕉觅云应助艾登登采纳,获得10
16秒前
一诺相许完成签到 ,获得积分10
17秒前
xwz发布了新的文献求助10
17秒前
斯文败类应助虚拟的惜筠采纳,获得10
19秒前
科目三应助人参采纳,获得10
19秒前
科研通AI2S应助不敢装睡采纳,获得10
20秒前
安详的冬瓜完成签到,获得积分10
21秒前
xwz完成签到,获得积分10
22秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Production Logging: Theoretical and Interpretive Elements 3000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
THE STRUCTURES OF 'SHR' AND 'YOU' IN MANDARIN CHINESE 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3761949
求助须知:如何正确求助?哪些是违规求助? 3305642
关于积分的说明 10135083
捐赠科研通 3019747
什么是DOI,文献DOI怎么找? 1658374
邀请新用户注册赠送积分活动 792030
科研通“疑难数据库(出版商)”最低求助积分说明 754783